MediTrust Health Secures Triple Honors at '2022 Future Healthcare 100' Awards and Files for Hong Kong IPO

From June 14 to June 18, the 6th Future Healthcare Top 100 Conference will be held for the first time in an innovative “Cloud Summit” format. Themed around “China’s Story,” this year’s conference will analyze industry hotspots from five dimensions—policy orientation, technological frontiers, capital perspectives, industrial innovation, and market demand—interpret development trends in the future healthcare industry, and drive transformative change in the innovative healthcare sector.

At the 6th Future Healthcare Top 100 Conference, VCBeat released the “2022 Future Healthcare Top 100 Series Rankings.” MediTrust Health won three awards in recognition of its outstanding performance in the healthcare sector over the past year.

The “Top 100 Future Healthcare” list is jointly launched by VCBeat, VB100, and Eggshell Research Institute, aiming to select Chinese innovative healthcare pioneers that truly represent the future of healthcare, identify the core forces driving China’s future healthcare industry, and promote innovation and transformation in the health and medical sector.

As the most anticipated annual ranking in the life and health sector by industry and capital circles, the 2022 Future Healthcare Top 100 series includes several major awards: the Future Healthcare Top 100 Main List, the Future Healthcare Top 100 Value Sector List, the Future Healthcare Top 100 Pengcheng Award, and the Future Healthcare Top 100 Weilan Award.

After undergoing a rigorous selection process that included corporate registration, institutional recommendations, expert reviews, and cross-verification, MediTrust Health has once again been shortlisted for the “2020-2021 Future Healthcare 100 · Innovative Medical Services List,” climbing to fifth place.

MediTrust Health was also awarded the “Pengcheng Award · Enterprise of the Year” for its outstanding performance across multiple dimensions, including annual value growth, innovation breakthroughs, and social responsibility.

Zhang Xiaodong, Founder and CEO of MediTrust Health, has been honored with the “Weilan Award · Entrepreneur Leader of the Year” in recognition of his outstanding capabilities across multiple dimensions, including personal innovation, industry influence, and corporate leadership. Under Mr. Zhang’s leadership, MediTrust Health has rapidly evolved over the past five years into a leading innovative healthcare service platform in the industry. The company has established a diversified business ecosystem encompassing patient services, commercial insurance services, and pharmaceutical enterprise services, continuously delivering higher-quality healthcare solutions to Chinese patients and contributing to the development of China’s multi-tiered healthcare security system.

At the conference, VCBeat VB100 also released the “2022 Future Healthcare 100 Enterprises Growth Report.” This report provides a comprehensive analysis of data on companies listed in the main ranking of the 2022 Future Healthcare 100, covering aspects such as valuation, geographic distribution, founding date, and financing rounds. It summarizes patterns of enterprise growth and trends in industry evolution, offering reference and insights for healthcare companies and entrepreneurs. As a high-growth company on the list, MediTrust Health was included as a case study in the report.

This conference brought together innovators from various sectors, including the healthcare industry, to jointly discuss hot topics concerning the development of the healthcare sector through immersive online presentations and dialogues. Qi Lei, CFO of MediTrust Health, attended the Strategic Summit of this year’s VB100 Conference and delivered a keynote speech titled “Digital Healthcare Technology Innovation: Providing Affordable Healthcare Coverage for the Public.”

Qi Lei, CFO of MediTrust Health, provided a comprehensive analysis of the current development status of China’s healthcare market from multiple dimensions, including supply, demand, and payment. He believes that China’s healthcare market is facing significant development opportunities. From the supply side, the acceleration of new drug launches and the continuous emergence of new therapies have led to an unprecedented richness in offerings. On the demand side, rising per capita GDP has boosted consumer spending power, while rapid population aging has spurred higher-level healthcare demands. Regarding payment, the basic medical insurance fund remains under sustained pressure. Meanwhile, commercial health insurance products, which are well-developed in overseas markets, are still in their early stages in China. As a result, out-of-pocket expenses account for approximately 50% of total healthcare expenditures in China.

“Compared with mature healthcare markets abroad, China’s healthcare market has yet to develop major payers beyond basic medical insurance. The pharmacy sector is characterized by homogeneous competition, while public hospitals hold a dominant position but have not achieved chain-based or group-based consolidation. The pharmaceutical industry is still in the process of development. Overall, both the supply and payment sides of healthcare remain highly fragmented, presenting unique challenges for China’s healthcare market.” Qi Lei, CFO of MediTrust Health, pointed out that China’s healthcare services market urgently needs an ecosystem platform capable of integrating resources from payers, providers, and other stakeholders. Such a platform would help build a multi-tiered healthcare security system with basic medical insurance as the mainstay, supplemented by urban policy-based insurance as supplementary medical coverage, and further layered with commercial health insurance and out-of-pocket payments.

As a pioneer of the “Internet + Healthcare + Pharmaceuticals + Insurance” ecosystem, MediTrust Health serves as a vital link connecting all stakeholders, dedicated to integrating resources from the pharmaceutical, insurance, and internet technology sectors. Its mission is to effectively alleviate patients’ financial burdens and make high-quality medical resources accessible to more families. Under MediTrust Health, its three core business segments—Kangfu Health, Kangfu Smart Pharma, and Kangfu Smart Insurance—work in close synergy. Leveraging digital healthcare innovations, they bridge the healthcare, pharmaceutical, and insurance industries. By empowering B-side pharmaceutical companies and insurers, MediTrust Health provides C-side users and their families with high-quality, affordable medical coverage and health services.